Alkermes plc (ALKS)
Market Cap | 4.09B |
Revenue (ttm) | 1.73B |
Net Income (ttm) | 434.43M |
Shares Out | 169.22M |
EPS (ttm) | 2.55 |
PE Ratio | 9.49 |
Forward PE | 8.84 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,188,339 |
Open | 24.40 |
Previous Close | 24.39 |
Day's Range | 24.11 - 24.46 |
52-Week Range | 22.01 - 32.88 |
Beta | 0.44 |
Analysts | Buy |
Price Target | 36.50 (+50.89%) |
Earnings Date | Jul 24, 2024 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $36.5, which is an increase of 50.89% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/c/r/press5-2458539.jpg)
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested — — ALKS...
![](https://cdn.snapi.dev/images/v1/m/h/conf14-2452463.jpg)
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN , May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Jefferies Health...
![](https://cdn.snapi.dev/images/v1/o/u/conf10-2449415.jpg)
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations – – Findings Fr...
![](https://cdn.snapi.dev/images/v1/k/q/press5-2428918.jpg)
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ̶ DU...
![](https://cdn.snapi.dev/images/v1/i/8/press11-2405493.jpg)
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In conne...
![](https://cdn.snapi.dev/images/v1/q/f/press14-2402243.jpg)
Alkermes plc Reports First Quarter 2024 Financial Results
— First Quarter Revenues of $350.4 Million — — GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 — — Company ...
![](https://cdn.snapi.dev/images/v1/z/g/press15-2387629.jpg)
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compar...
![](https://cdn.snapi.dev/images/v1/f/p/conf18-2376901.jpg)
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
![](https://cdn.snapi.dev/images/v1/g/w/press3-2362655.jpg)
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both ...
![](https://cdn.snapi.dev/images/v1/8/w/press15-2360601.jpg)
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS...
![](https://cdn.snapi.dev/images/v1/8/q/press2-2312748.jpg)
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
DUBLIN , March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board).
![](https://cdn.snapi.dev/images/v1/3/p/press9-2277684.jpg)
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
— Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2....
![](https://cdn.snapi.dev/images/v1/k/d/conf16-2268154.jpg)
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
![](https://cdn.snapi.dev/images/v1/s/p/conf12-2215445.jpg)
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. M...
![](https://cdn.snapi.dev/images/v1/x/h/press10-2214364.jpg)
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — DUBLIN , Jan. 3, ...
![](https://cdn.snapi.dev/images/v1/6/f/press16-2195846.jpg)
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
DUBLIN , Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Irelan...
![](https://cdn.snapi.dev/images/v1/z/c/press15-2158912.jpg)
Alkermes Completes Separation of Oncology Business
— Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — — Alkermes Provides Updated Financial Expectations for 2023 — DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS...
![](https://cdn.snapi.dev/images/v1/6/m/press18-2145189.jpg)
Alkermes to Participate in the Jefferies London Healthcare Conference
DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14,...
![](https://cdn.snapi.dev/images/v1/r/w/press6-2131787.jpg)
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
DUBLIN , Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was d...
![](https://cdn.snapi.dev/images/v1/t/i/press14-2119317.jpg)
Alkermes plc Reports Third Quarter 2023 Financial Results
— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million ...
![](https://cdn.snapi.dev/images/v1/y/l/press7-2115039.jpg)
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
— Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested...
![](https://cdn.snapi.dev/images/v1/b/o/conf17-2109751.jpg)
Alkermes to Report Third Quarter Financial Results on October 25, 2023
DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
![](https://cdn.snapi.dev/images/v1/a/g/conf14-2097878.jpg)
Mural Oncology to Host Investor Webcast on October 17
— Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10, 2023 /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans...
![](https://cdn.snapi.dev/images/v1/w/b/conf11-2096387.jpg)
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist — DUBLIN , Oct. 10, 2023...
![](https://cdn.snapi.dev/images/v1/h/b/press14-2057140.jpg)
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy — DUBLIN , Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ann...